Product menu

Initial maintenance therapy for symptomatic COPD patients, recommended by NICE and GOLD1,2

Adapted visual shows only GOLD groups A and B and NICE guidance for patients with no asthmatic features or features suggesting steroid responsiveness.

NA

Before starting inhaled therapy GOLD and NICE recommend considering non-pharmacological approaches, such as smoking cessation, pulmonary rehabilitation etc.
A short-acting bronchodilator is recommended by GOLD and NICE for additional immediate symptom relief, if needed.
GSK-adapted from © 2024 Global Strategy for the Diagnosis, Management and Prevention of COPD. All rights reserved. Use is by express license from the owner. GSK-adapted from © NICE 2019. COPD in over 16s: diagnosis and management. Available from www.nice.org.uk/guidance/ng115. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this material.
CAT, COPD Assessment Test; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; mMRC Modified Medical Research Council Dyspnoea Scale

DOWNLOAD NICE AND GOLD SUMMARY

This PDF must be printed on A4 paper only as A4 in size.

References:

  1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2024 Report. Date accessed: February 2024.
  2. COPD in over 16s: diagnosis and management NICE guideline [NG115]. Last updated: July 2019. Available from: Last accessed: February 2024.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.

February 2024 | PM-GB-UCV-WCNT-230033 (V1.0)